Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 891348, 5 pages
Clinical Study

Efficacy of Zonisamide in Migraineurs with Nonresponse to Topiramate

1Department of Veterinary Internal Medicine and Geriatrics, Kangwon National University, Gangwon-do, Republic of Korea
2Institute of Catholic Integrative Medicine (ICIM), Incheon St. Mary’s Hospital, Catholic University of Korea, Incheon, Republic of Korea
3Department of Neurology, Seoul National University Hospital, 101 Daehakro, Chongno-ku, Seoul 110-744, Republic of Korea

Received 21 March 2014; Revised 28 May 2014; Accepted 17 June 2014; Published 2 July 2014

Academic Editor: Luca Prosperini

Copyright © 2014 Jin-Young Chung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This study investigated another type of carbonic anhydrase inhibitor and antiepileptic drug, zonisamide, in order to evaluate its potential effectiveness for migraine prophylaxis refractory to topiramate, and to assess intolerability to adverse events, paresthesia in particular. This is an open-labeled retrospective single center study. We included headache patients who met the requirement of migraine without aura and were refractory to topiramate. Patients were treated only with zonisamide 100 mg/day, directly switching from topiramate. Patients were monitored every month for three months. A positive response to treatment (responders) was defined as a 50% or greater reduction in headache days at three months after study commencement, compared with baseline. One hundred and twenty migraineurs who were refractory to topiramate were recruited. Compared with baseline, headache days with zonisamide showed a decrease, compared with baseline (). Two patients complained of adverse effects, such as paresthesia. These results suggest that zonisamide is effective for migraine prophylaxis refractory to topiramate, or intolerable patients due to topiramate-induced paresthesia.